Skip to main content
. 2021 Apr 7;13(8):1766. doi: 10.3390/cancers13081766

Figure 7.

Figure 7

BTLA blockade depletes leukemic cells and increases NK cell-mediated cytotoxicity. (A) PBMCs from patients with CLL were treated with blocking anti-BTLA mAb or control IgG (10 µg/mL) and absolute leukemic cell count was evaluated at indicated timepoints. (B) The effect of BTLA blockade on NK cell-mediated cytotoxicity was evaluated by calcein-AM assay. PBMCs from patients were treated with blocking anti-BTLA mAb or control IgG (10 µg/mL) (n = 11) for 72 h and then co-cultured with MEC-1 cell line (pre-treated with 10 µg/mL of rituximab or control IgG for 30 min) at 25:1 (effector: target) ratio for 4h. * p < 0.05, ** p < 0.01.